高同型半胱氨酸血症（HHcy）是动脉粥样硬化（AS）的独立危险因素。内皮间质转化（endothelial mesenchymal Transition，EndMT）是指内皮细胞失去内皮细胞形态和特征基因表达，而获得与间充质细胞相关的表型特征和基因表达的过程。大量研究证实EndMT参与动脉粥样硬化的形成。梓醇是地黄的活性成分之一，具有抗氧化、抗炎、抗肿瘤、神经保护等生物活性。研究表明，梓醇可以减少高糖或高脂肪诱发的动脉粥样硬化斑块。然而，梓醇对HHCY诱导的EndMT的影响尚不清楚。采用体外HHcy处理的原代人脐静脉内皮细胞（HUVEC）构建细胞模型，并给予抗氧化剂N-乙酰半胱氨酸（NAC）和过氧化氢酶醇。体内C57BL/6N小鼠给予4.4%高蛋氨酸饲料喂养，构建HHcy小鼠模型，并用梓醇处理。结果表明，hhcy可诱导内皮细胞向间充质细胞形态转化，增加细胞内ROS含量，上调α-SMA、N-cadherin、p-p65蛋白表达，下调VE-cadherin、CD31蛋白表达，诱导主动脉根部内皮病理改变，主动脉内皮ROS含量增加。梓醇逆转了这些hhcy诱导的结果。梓醇抑制HHcy诱导的EndMT，其潜在机制可能与ROS/NF-κB信号通路有关。梓醇可能是治疗 HHcy 相关 AS 的潜在药物。© 2024。作者。

Hyperhomocysteinemia (HHcy) is an independent risk factor for atherosclerosis (AS). Endothelial mesenchymal transition (EndMT) refers to the process in which endothelial cells lose endothelial cell morphology and characteristic gene expression, and acquire phenotypic characteristics and gene expression related to mesenchymal cells. Numerous studies have confirmed that EndMT is involved in the formation of atherosclerosis. Catalpol is one of the active components of Rehmannia, which has antioxidant, anti-inflammatory, anti-tumor, neuroprotective and other biological activities. Studies have shown that catalpol can reduce atherosclerotic plaque induced by high sugar or fat. However, the effect of catalpol on HHCY-induced EndMT is unclear.In vitro HHcy-treated primary human umbilical vein endothelial cells (HUVECs) were used to construct a cell model, and the antioxidants N-acetylcysteine (NAC) and catalase alcohol were administered. In vivo C57BL/6N mice were given a diet fed with 4.4% high methionine chow to construct a HHcy mice model and were treated with catalpol. The results showed that hhcy could induce morphological transformation of endothelial cells into mesenchymal cells, increase intracellular ROS content, up-regulate α-SMA, N-cadherin, p-p65 protein expression, down-regulate VE-cadherin, CD31 protein expression, induce pathological changes of aortic root endothelium, and increase aortic endothelial ROS content. Catalpol reversed these hhcy induced outcomes.Catalpol inhibits HHcy-induced EndMT, and the underlying mechanism may be related to the ROS/NF-κB signaling pathway. Catalpol may be a potential drug for the treatment of HHcy-related AS.© 2024. The Author(s).